JOURNEY MEDICAL CORPOR

NetDania - New 12 months High: JOURNEY MEDICAL CORPORATION - COMMON STOCK

20 12 2023 12:19:59 提供 NetDania Notify

NetDania - New 12 months High: JOURNEY MEDICAL CORPORATION - COMMON STOCK

19 12 2023 08:45:11 提供 NetDania Notify

NetDania - New 12 months High: JOURNEY MEDICAL CORPORATION - COMMON STOCK

18 12 2023 09:50:29 提供 NetDania Notify

NetDania - New 12 months High: JOURNEY MEDICAL CORPORATION - COMMON STOCK

07 12 2023 08:45:04 提供 NetDania Notify

NetDania - New 12 months High: JOURNEY MEDICAL CORPORATION - COMMON STOCK

06 12 2023 09:26:29 提供 NetDania Notify

Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea

06 12 2023 07:00:51 提供 Nasdaq GlobeNewswire

Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

07 11 2023 15:01:18 提供 Nasdaq GlobeNewswire

Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023

31 10 2023 07:30:12 提供 Nasdaq GlobeNewswire

Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg)

20 10 2023 07:30:59 提供 Nasdaq GlobeNewswire

Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian Nations

06 9 2023 07:00:04 提供 Nasdaq GlobeNewswire

Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

08 8 2023 15:01:33 提供 Nasdaq GlobeNewswire

Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023

02 8 2023 15:01:42 提供 Nasdaq GlobeNewswire

Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023

19 7 2023 07:30:00 提供 Nasdaq GlobeNewswire

Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults

11 7 2023 07:30:20 提供 Nasdaq GlobeNewswire

Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of July 10, 2023

03 7 2023 07:00:00 提供 Nasdaq GlobeNewswire

Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects

13 6 2023 07:30:59 提供 Nasdaq GlobeNewswire

Journey Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

22 5 2023 15:01:31 提供 Nasdaq GlobeNewswire

Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023

19 5 2023 15:01:27 提供 Nasdaq GlobeNewswire

Journey Medical Corporation Announces Postponement of First Quarter Financial Results Release and Conference Call

11 5 2023 15:01:01 提供 Nasdaq GlobeNewswire

Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 11, 2023

04 5 2023 08:00:26 提供 Nasdaq GlobeNewswire